You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
30
Nov 21
Press Release – quarterly statement (call-date Q3)
31
Aug 21
Publication half-yearly financial statements
13
Jul 21
Annual General Meeting
May 21
Press Release – quarterly statement (call-date Q1)
26
Publication of Annual Report
21
Apr 21
Press Release for Annual Report
23
Nov 20
24
Aug 20
Jul 20
18
May 20
11
25
Mar 20
22
Nov 19
Aug 19
10
Jul 19
20
May 19
06
Mar 19
Nov
2016
Aug
09
Jun 16
May 16
Apr 16
16
Mar 16
27
Nov 15
Press Release for Q3 Report
28
Aug 15
Jun 15
May 15
Press Release for Q1 Report
15
Apr 15
Mar 15
Nov 14
Aug 14
May 14
Apr 14
Mar 14
2013
Publication Interim Report within 2nd HY
May 13
May
30 November 2023
HAEMATO AG: Termination of listing in the Open Market
16 November 2023
HAEMATO AG publishes figures for the third quarter of 2023: Sales increase of around 13% compared to the same period of the previous year, strong increase in EBIT margin and significant increase in
15 November 2023
Termination of the botulinum toxin project
31 August 2023
HAEMATO AG publishes figures for the first half of 2023
31 May 2023
HAEMATO AG with a strong start into the year 2023: Revenue increase of over 25% compared to the same quarter of the previous year and disproportionate increase in the operating result
16 May 2023
HAEMATO AG: Dividend of EUR 1.20
30 October 2023
Half-yearly financial statements 2023
9 June 2023
Annual financial statements 2022
7 October 2022
Half-yearly financial statements 2022
15 December 2023
Original-Research: HAEMATO AG (von GBC AG): ausgesetzt
Original-Research: HAEMATO AG (von GBC AG): suspended
13 December 2023
Original-Research: Haemato AG (von First Berlin Equity Research GmbH): Not Rated
18 September 2023
Original-Research: Haemato AG (von First Berlin Equity Research GmbH): Kaufen
14 September 2023
Original-Research: HAEMATO AG (von GBC AG): BUY
Original-Research: HAEMATO AG (von GBC AG): Kaufen